H&R Block is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical improvement and pre-market strength, but the broader picture is mixed to negative: analysts are cutting targets, hedge funds and insiders are selling, and the next earnings event is close. I would not call this a clear buy today; it is better suited to a wait-and-see or hold stance.
HRB is trading pre-market at 31.95, up 0.69%, which is slightly supportive short term. MACD is positive and expanding, suggesting improving momentum. RSI_6 at 57.686 is neutral to mildly constructive. However, the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5, which means the longer-term trend is still weak. Price is sitting near pivot resistance at 31.268 and below first resistance at 32.36, so upside from here is not yet convincing. The technical setup is mixed: short-term momentum is improving, but the longer-term trend has not turned bullish.

["Pre-market price is positive at 31.95, indicating immediate buying interest.", "MACD histogram is positive and expanding, which supports improving momentum.", "Revenue in the latest reported quarter grew 11.05% YoY in 2026/Q2.", "A notable investor, Prevatt Capital, increased its stake by 360,000 shares in Q1 2026."]
["Goldman Sachs cut its price target sharply to $32 from $48 and kept a Sell rating.", "Goldman highlighted seasonal weakness in Q2 and risks of limited growth and market share loss into the 2026 tax season.", "Hedge funds are selling heavily, with selling up 4249.89% over the last quarter.", "Insiders are also selling, with selling up 309.28% over the last month.", "Net income was negative at -242.444 million in 2026/Q2, showing weak profitability.", "Gross margin deteriorated sharply to -70.93.", "The company faces competitive pressure from TurboTax and AI-native entrants.", "Earnings are upcoming on 2026-05-06 after hours, which may keep buyers cautious."]
In 2026/Q2, revenue increased 11.05% year over year to 198.865 million, which is a positive top-line trend. However, profitability remains weak: net income was -242.444 million and gross margin fell to -70.93. EPS was still negative at -1.92, even though it improved 6.67% year over year. The latest quarter shows sales growth, but not yet strong earnings quality or margin recovery. For a long-term beginner investor, this does not yet look like a clear fundamental turnaround.
Analyst sentiment has turned more cautious overall. Goldman Sachs downgraded its price target sharply to $32 from $48 and kept a Sell rating, citing seasonal weakness and competitive risks. Barrington was more constructive, lowering its target to $50 from $62 while keeping Outperform and noting Q1 results beat expectations and FY2026 guidance was reaffirmed. The Wall Street view is split, but the recent trend in targets is downward, and the more recent high-profile call is bearish.